OSLO, Norway, April 2, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) notes that promising results from its preclinical research collaboration to develop a novel CD37-targeting alpha therapy for B-cell tumours have been reported today in an oral presentation at TAT11, the 11th...
from PR Newswire: https://ift.tt/2I4uyhP
No comments:
Post a Comment